MedTrace Logo

Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML

NCT06827899 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-02-20

No results posted yet for this study

Summary

A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)

Conditions

Interventions

DRUG

veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG)

Specified dose on specified days

Sponsors & Collaborators

  • Fujian Provincial Hospital

    collaborator OTHER

  • Fujian Cancer Hospital

    collaborator OTHER_GOV

  • Zhangzhou Affiliated Hospital of Fujian Medical University

    collaborator OTHER

  • Jieyang People's Hospital

    collaborator OTHER

  • Huizhou Municipal Central Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Principal Investigators

  • Bing Xu · The First Aiffiliated hosptical of xiamen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2026-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06827899 on ClinicalTrials.gov